BACKGROUND Mesenchymal stem cell-derived extracellular vesicles(MSC-EVs)can traverse the blood-brain barrier due to their small size.This characteristic makes them a research hotspot for the treatment of Parkinson’s ...BACKGROUND Mesenchymal stem cell-derived extracellular vesicles(MSC-EVs)can traverse the blood-brain barrier due to their small size.This characteristic makes them a research hotspot for the treatment of Parkinson’s disease(PD)and is expected to be a potentially revolutionary strategy for treating PD.Despite this,no summary of clinical trial results has been reported.AIM To assess the efficacy and durability of MSC-EVs in treating PD.METHODS Systematic searches were conducted in four electronic databases until June 2024 to collect studies on the use of MSC-EVs for this purpose.Thirteen relevant randomized controlled trials,encompassing 16 experiments,were selected for inclusion.RESULTS Behavioral assessments,including the rotarod and apomorphine turning behavior tests,indicated improvements in motor coordination(P<0.00001);the Pole test and the Wire-hang test showed enhanced limb motor agility and synchronization(P=0.003 and P<0.00001,respectively).Histopathologically,there was a reduction in inflammatory markers such as tumor necrosis factor-αand interleukin-6(P=0.03 and P=0.01,respectively)and an increase in tyrosine hydroxylase-positive cells in the lesion areas(P<0.00001).CONCLUSION MSC-EV therapy for PD is a gradual process,with significant improvements observable more than 2 weeks after administration and lasting at least 8 weeks.This study is the first to demonstrate the efficacy and durability of MSC-EV treatment in PD.展开更多
基金Supported by the National Natural Science Foundation of China,No.32060232and the Natural Science Foundation of Jiangxi Province,No.20212BAB206075.
文摘BACKGROUND Mesenchymal stem cell-derived extracellular vesicles(MSC-EVs)can traverse the blood-brain barrier due to their small size.This characteristic makes them a research hotspot for the treatment of Parkinson’s disease(PD)and is expected to be a potentially revolutionary strategy for treating PD.Despite this,no summary of clinical trial results has been reported.AIM To assess the efficacy and durability of MSC-EVs in treating PD.METHODS Systematic searches were conducted in four electronic databases until June 2024 to collect studies on the use of MSC-EVs for this purpose.Thirteen relevant randomized controlled trials,encompassing 16 experiments,were selected for inclusion.RESULTS Behavioral assessments,including the rotarod and apomorphine turning behavior tests,indicated improvements in motor coordination(P<0.00001);the Pole test and the Wire-hang test showed enhanced limb motor agility and synchronization(P=0.003 and P<0.00001,respectively).Histopathologically,there was a reduction in inflammatory markers such as tumor necrosis factor-αand interleukin-6(P=0.03 and P=0.01,respectively)and an increase in tyrosine hydroxylase-positive cells in the lesion areas(P<0.00001).CONCLUSION MSC-EV therapy for PD is a gradual process,with significant improvements observable more than 2 weeks after administration and lasting at least 8 weeks.This study is the first to demonstrate the efficacy and durability of MSC-EV treatment in PD.
